# Tenaya Therapeutics, Inc.: overview

TNYA · Nasdaq · CIK 1858848 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tnya.md) · [Financials](/companies/tnya/financials.md) · [Filings](/companies/tnya/filings.md) · [Insiders](/companies/tnya/insiders.md)

Latest reported revenue: [$1.1m](/filings/0001193125-26-335140.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335140).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001193125-26-209084.md) | [0.0](/filings/0001193125-26-335140.md) | not reported | not reported | [0.2](/filings/0001193125-26-209084.md) | [1.1](/filings/0001193125-26-335140.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(8917.8%)](/filings/0001193125-26-209084.md) | [(3971.9%)](/filings/0001193125-26-335140.md) |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(8565.3%)](/filings/0001193125-26-335140.md) | [(3909.3%)](/filings/0001193125-26-335140.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0001193125-25-273239.md) | not reported | [(0.24)](/filings/0001193125-26-209084.md) | [(0.14)](/filings/0001193125-26-335140.md) | [(0.12)](/filings/0001193125-25-273239.md) | not reported | [(0.09)](/filings/0001193125-26-209084.md) | [(0.20)](/filings/0001193125-26-335140.md) |
| Free cash flow | $m | [(20.0) d](/filings/0001193125-25-273239.md) | [(18.6) d](/filings/0001193125-26-102252.md) | [(23.5)](/filings/0001193125-26-209084.md) | [(15.8) d](/filings/0001193125-26-335140.md) | [(15.6) d](/filings/0001193125-25-273239.md) | [(14.0) d](/filings/0001193125-26-102252.md) | [(19.2)](/filings/0001193125-26-209084.md) | [(3.7) d](/filings/0001193125-26-335140.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(4.10)](/filings/0000950170-23-006725.md) | [(2.76)](/filings/0000950170-24-032828.md) | [(1.68)](/filings/0000950170-25-036329.md) | [(1.31)](/filings/0001193125-26-102252.md) | [(0.59)](/filings/0001193125-26-102252.md) |
| Free cash flow | $m | [(85.9)](/filings/0000950170-23-006725.md) | [(125)](/filings/0000950170-24-032828.md) | [(103)](/filings/0000950170-25-036329.md) | [(91.5)](/filings/0001193125-26-102252.md) | [(68.9)](/filings/0001193125-26-102252.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tnya/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.2m | 7,101,263 |  | Reduced −1,381,025 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $4.8m | 6,429,648 |  | Added +972,982 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $3.4m | 4,566,774 |  | Added +366,774 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $3.2m | 4,281,100 |  | Added +567,339 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.0m | 4,008,719 |  | Added +304,764 |
| [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $2.9m | 3,863,115 |  | Reduced −423,818 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $2.6m | 3,503,178 |  | Added +797,788 |
| [Burkehill Global Management, LP](/funds/1904549.md) | 2026-06-30 | $1.5m | 2,000,000 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.4m | 1,834,674 |  | Added +274,735 |
| [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $1.1m | 1,555,500 |  | Added +47,700 |

## Recent filings

[All 347 filings](/companies/tnya/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 16:47 ET | [DEF 14A](/filings/0001193125-26-430591.md) | Proxy statement, period 2026-12-09 | 0001193125-26-430591 |
| 2026-08-05 | 20:15 ET | [10-Q](/filings/0001193125-26-335140.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335140 |
| 2026-08-05 | 20:10 ET | [8-K](/filings/0001193125-26-335098.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335098 |
| 2026-07-02 | 21:00 ET | [8-K](/filings/0001193125-26-294879.md) | 1.02 Termination of a material agreement | 0001193125-26-294879 |
| 2026-06-29 | 13:00 ET | [8-K](/filings/0001193125-26-286957.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-286957 |
| 2026-05-29 | 21:04 ET | [8-K](/filings/0001193125-26-248680.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-248680 |
| 2026-05-06 | 20:24 ET | [10-Q](/filings/0001193125-26-209084.md) | Quarterly report, period 2026-03-31 | 0001193125-26-209084 |
| 2026-05-06 | 20:11 ET | [8-K](/filings/0001193125-26-208975.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208975 |
| 2026-04-16 | 13:00 ET | [DEF 14A](/filings/0001193125-26-158079.md) | Proxy statement, period 2026-05-27 | 0001193125-26-158079 |
| 2026-03-11 | 20:28 ET | [10-K](/filings/0001193125-26-102252.md) | Annual report, period 2025-12-31 | 0001193125-26-102252 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-102252.md), filed Mar 11, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/293d86fc-7c16-4288-a199-a7fff08aad0c)

## About the filer

- CIK: 1858848
- Tickers: TNYA
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.